ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,222.68
      0.16%
      US Tech 100
      17,650.00
      0.05%
      Dow Jones
      39,512.84
      0.32%
      Brent Oil
      82.355
      -0.04%
      Bitcoin
      60,901.90
      -0.89%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      Symbol: 
      		Date:
      Sort by:
      DateTimeSourceHeadlineSymbolCompany
      05/13/20241:00AMGlobeNewswire Inc.Corbion reports the progress of its € 20 million share buyback program 6 May – 10 May 2024EU:CRBNCorbion N.V.
      05/13/20241:00AMGlobeNewswire Inc.Communiqué de presse : Sanofi investit plus d’un milliard d’euros supplémentaires dans la production de médicaments en France, en plus des 2,5 milliards d’euros déjà engagés dans de grands projets de souveraineté sanitaireBIT:1SANSanofi
      05/13/20241:00AMGlobeNewswire Inc.Air France-KLM a remboursé les 48 millions d'euros restants d'OCEANE à échéance 2026TG:AFRAir France KLM
      05/13/20241:00AMGlobeNewswire Inc.Air France-KLM a remboursé les 48 millions d'euros restants d'OCEANE à échéance 2026LSE:AIRFAir France-Klm
      05/13/20241:00AMGlobeNewswire Inc.Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereigntyBIT:SANFSanofi
      05/13/20241:00AMGlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)NASDAQ:SNYSanofi
      05/13/20241:00AMGlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)NASDAQ:REGNRegeneron Pharmaceuticals Inc
      05/13/20241:00AMGlobeNewswire Inc.Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya VaccineTG:AYJValneva SE
      05/13/20241:00AMGlobeNewswire Inc.Norsk Hydro: Changes in Hydro’s Executive Leadership TeamTG:A2R0MANorsk Hydro ASA
      05/13/20241:00AMGlobeNewswire Inc.Valneva annonce de nouveaux résultats positifs chez les adolescents pour l’étude pivot de Phase 3 de son vaccin à dose unique contre le chikungunyaTG:AYJValneva SE
      05/13/20241:00AMGlobeNewswire Inc.Communiqué de presse : Sanofi investit plus d’un milliard d’euros supplémentaires dans la production de médicaments en France, en plus des 2,5 milliards d’euros déjà engagés dans de grands projets de souveraineté sanitaireTG:SNWSanofi
      05/13/20241:00AMGlobeNewswire Inc.Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya VaccineEU:VLAValneva SE
      05/13/20241:00AMGlobeNewswire Inc.Valneva annonce de nouveaux résultats positifs chez les adolescents pour l’étude pivot de Phase 3 de son vaccin à dose unique contre le chikungunyaEU:VLAValneva SE
      05/13/20241:00AMGlobeNewswire Inc.Norsk Hydro: Changes in Hydro’s Executive Leadership TeamTG:NHYLucapa Diamond Company Ltd
      05/13/20241:00AMGlobeNewswire Inc.Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya VaccineLSE:0OB3Valneva Se
      05/13/20241:00AMGlobeNewswire Inc.Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya VaccineEU:VLAValneva SE
      05/13/20241:00AMGlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)EU:SANSanofi
      05/13/20241:00AMGlobeNewswire Inc.Corbion reports the progress of its € 20 million share buyback program 6 May – 10 May 2024TG:CSUACorbion N.V.
      05/13/20241:00AMGlobeNewswire Inc.Start of Day Message
      05/13/20241:00AMGlobeNewswire Inc.Valneva annonce de nouveaux résultats positifs chez les adolescents pour l’étude pivot de Phase 3 de son vaccin à dose unique contre le chikungunyaLSE:0OB3Valneva Se
      05/13/20241:00AMGlobeNewswire Inc.Communiqué de presse : Sanofi investit plus d’un milliard d’euros supplémentaires dans la production de médicaments en France, en plus des 2,5 milliards d’euros déjà engagés dans de grands projets de souveraineté sanitaireBIT:SANFSanofi
      05/13/20241:00AMGlobeNewswire Inc.Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereigntyTG:SNWSanofi
      05/13/20241:00AMBusiness WireCTP doubles in size only three years after Euronext listing
      05/13/20241:00AMGlobeNewswire Inc.Air France-KLM a remboursé les 48 millions d'euros restants d'OCEANE à échéance 2026BIT:AFAir France KLM
      05/13/20241:00AMGlobeNewswire Inc.Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereigntyEU:SANSanofi
      05/13/20241:00AMGlobeNewswire Inc.Air France-KLM repaid remaining €48 million of OCEANE 2026 bondsBIT:AFAir France KLM
      05/13/20241:00AMGlobeNewswire Inc.Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya VaccineVLAP
      05/13/20241:00AMGlobeNewswire Inc.Communiqué de presse : Sanofi investit plus d’un milliard d’euros supplémentaires dans la production de médicaments en France, en plus des 2,5 milliards d’euros déjà engagés dans de grands projets de souveraineté sanitaireEU:SANSanofi
      05/13/20241:00AMGlobeNewswire Inc.Air France-KLM repaid remaining €48 million of OCEANE 2026 bondsLSE:AIRFAir France-Klm
      05/13/20241:00AMGlobeNewswire Inc.Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereigntyBIT:1SANSanofi